<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Alaeras</title>
	<atom:link href="http://alaeras.com/feed" rel="self" type="application/rss+xml" />
	<link>http://alaeras.com</link>
	<description>The next generation of drug delivery solutions.</description>
	<lastBuildDate>Wed, 05 May 2010 13:44:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Inahalable Drug Delivery</title>
		<link>http://alaeras.com/inahalable-drug-delivery.html</link>
		<comments>http://alaeras.com/inahalable-drug-delivery.html#comments</comments>
		<pubDate>Thu, 25 Mar 2010 16:22:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://alaeras.com/?p=110</guid>
		<description><![CDATA[Inhalable delivery tech worth $38bn says GIA
By Staff Reporter, 24-Mar-2010, Reprinted with permission

Related topics: Globalisation, Materials &#38; Formulation, Drug delivery systems
The increasing incidence of chronic and “lifestyle” related disorders will fuel demand for inhalable delivery technologies over the next five years, according to a Global Industry Analysts (GIA) report. 
GIA explained that: “Primary drivers of [...]]]></description>
		<wfw:commentRss>http://alaeras.com/inahalable-drug-delivery.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gates to Donate $10B for Vaccine Research</title>
		<link>http://alaeras.com/gates-to-donate-10b-for-vaccine-research.html</link>
		<comments>http://alaeras.com/gates-to-donate-10b-for-vaccine-research.html#comments</comments>
		<pubDate>Mon, 01 Feb 2010 19:51:17 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://alaeras.com/?p=108</guid>
		<description><![CDATA[DAVOS, Switzerland — The Bill and Melinda Gates Foundation will donate $10 billion over the next decade to research new vaccines and bring them to the world&#8217;s poorest countries, the Microsoft co-founder and his wife said Friday.

Calling upon governments and business to also contribute, they said the money will produce higher immunization rates and aims [...]]]></description>
		<wfw:commentRss>http://alaeras.com/gates-to-donate-10b-for-vaccine-research.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bright Outlook for Vaccines</title>
		<link>http://alaeras.com/bright-outlook-for-vaccines.html</link>
		<comments>http://alaeras.com/bright-outlook-for-vaccines.html#comments</comments>
		<pubDate>Fri, 20 Nov 2009 18:56:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://alaeras.com/?p=100</guid>
		<description><![CDATA[Here are excerpts from a recent story appearing in the Raleigh News and Observer newspaper on November 20, 2009.

“Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they&#8217;re starting to give ailing pharmaceutical makers a shot in the arm.
Vaccines now are viewed as a crucial path to growth, as drugmakers [...]]]></description>
		<wfw:commentRss>http://alaeras.com/bright-outlook-for-vaccines.html/feed</wfw:commentRss>
		<slash:comments>9</slash:comments>
		</item>
		<item>
		<title>Wyrick Robbins Yates &amp; Ponton</title>
		<link>http://alaeras.com/wyrick-robbins-yates-ponton.html</link>
		<comments>http://alaeras.com/wyrick-robbins-yates-ponton.html#comments</comments>
		<pubDate>Mon, 28 Sep 2009 15:43:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://alaeras.com/?p=104</guid>
		<description><![CDATA[Alaeras announced today it has selected the law firm of Wyrick Robbins Yates and Ponton to provide its legal service. Located in Raleigh, North   Carolina, Wyrick has become one of the largest and most respected law firm in the Triangle.





]]></description>
		<wfw:commentRss>http://alaeras.com/wyrick-robbins-yates-ponton.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hilleman Laboratories</title>
		<link>http://alaeras.com/hilleman-laboratories.html</link>
		<comments>http://alaeras.com/hilleman-laboratories.html#comments</comments>
		<pubDate>Mon, 21 Sep 2009 21:43:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://alaeras.com/?p=95</guid>
		<description><![CDATA[Merck &#38; Co. and the Wellcome Trust have agreed to create a not-for-profit joint venture to develop low cost vaccines for poor countries around the world. The companies also announced that the initial investment would total 90 million pounds ($148 million) over a seven year period. Hilleman Laboratories, named after Merck scientist Maurice Hilleman, will [...]]]></description>
		<wfw:commentRss>http://alaeras.com/hilleman-laboratories.html/feed</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

